Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 17/20 | 1.00 |
| ▸ | ADORA2B | P29275 | 16/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.69 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3661085 | 0.91 | ADORA2A (0.83) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL24261356 | 0.88 | ADORA2A (0.79) | ADORA2AADORA2BADORA1 | |
| SCHEMBL13052127 | 0.87 | ADORA2A (0.86) | ADORA2AADORA2B | |
| SCHEMBL20785290 | 0.86 | ADORA2A (1.00) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20784297 | 0.85 | ADORA2B (0.74) | ADORA2AADORA2B | |
| SCHEMBL20784338 | 0.85 | ADORA2A (0.74) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL20784440 | 0.84 | ADORA2A (0.84) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL20784504 | 0.82 | ADORA2A (1.00) | ADORA2AADORA2BADORA3 | |
| SCHEMBL6858372 | 0.82 | ADORA2A (1.00) | ADORA2AADORA2BADORA1ADORA3 | |
| SCHEMBL3749902 | 0.82 | ADORA2A (0.77) | ADORA2AADORA2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | CORVUS PHARMACEUTICALS, INC. (US) | 2022-02-22 | — | — | US | disclosed |
| WO-2019046784-A1 | COMPOUNDS AND METHODS FOR MODULATING ADENOSINE A2B RECEPTOR AND ADENOSINE A2A RECEPTOR | CORVUS PHARMACEUTICALS, INC. (US) | 2019-03-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254686-B1 | Compounds and methods for modulating adenosine A2B receptor and adenosine A2A receptor | ADORA2A, ADORA2B, ADORA3 | ADORA2A 1/4885ADORA2B 2/4885ADORA1 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.